Characteristics of patients with COVID-19 and control donors
| Characteristics* . | Control (n = 25) . | Mild (n = 22) . | Severe (n = 46) . |
|---|---|---|---|
| Age, y | 48 (39-58) | 41 (32-50) | 58 (47-66) |
| Male | 10 (40%) | 9 (41%) | 23 (50%) |
| Respiratory support | |||
| Oxygen supplementation | 0 (0%) | 0 (0%) | 16 (35%) |
| Mechanical ventilation | 0 (0%) | 0 (0%) | 30 (65%) |
| SAPS II | – | – | 60 (47-68) |
| PaO2/FiO2 ratio | – | – | 152 (127-280) |
| Vasopressors† | 0 (0%) | 0 (0%) | 16 (35%) |
| Time from symptom onset to blood sample, d | 8 (6-16) | 11 (7-16) | |
| 28-d mortality | 0 (0%) | 0 (0%) | 18 (39%) |
| Comorbidities | |||
| Obesity | 2 (8%) | 1 (5%) | 10 (22%) |
| Hypertension | 2 (8%) | 4 (18%) | 25 (54%)‡ |
| Diabetes | 0 (0%) | 1 (5%) | 16 (35%)‡ |
| Cancer | 0 (0%) | 0 (0%) | 4 (9%) |
| Heart disease§ | 0 (0%) | 0 (0%) | 3 (7%) |
| Presenting symptoms | |||
| Cough | 0 (0%) | 8 (36%) | 26 (57%) |
| Fever | 0 (0%) | 8 (36%) | 29 (63%) |
| Dyspnea | 0 (0%) | 3 (14%) | 29 (63%) |
| Headache | 0 (0%) | 7 (32%) | 5 (11%) |
| Anosmia | 0 (0%) | 6 (27%) | 11 (24%) |
| Laboratory findings at admission | |||
| Leukocytes, ×1000/µL | – | 7.6 (6.2-15.5) | 13 (9.1-18.4) |
| Lymphocytes, cells/µL | – | 2156 (2015-2933) | 1057 (567-1540) |
| Monocytes, cells/µL | – | 447 (308-620) | 672 (473-848) |
| Platelet count, ×1000/µL | – | 188 (26-198) | 194 (155-268) |
| Characteristics* . | Control (n = 25) . | Mild (n = 22) . | Severe (n = 46) . |
|---|---|---|---|
| Age, y | 48 (39-58) | 41 (32-50) | 58 (47-66) |
| Male | 10 (40%) | 9 (41%) | 23 (50%) |
| Respiratory support | |||
| Oxygen supplementation | 0 (0%) | 0 (0%) | 16 (35%) |
| Mechanical ventilation | 0 (0%) | 0 (0%) | 30 (65%) |
| SAPS II | – | – | 60 (47-68) |
| PaO2/FiO2 ratio | – | – | 152 (127-280) |
| Vasopressors† | 0 (0%) | 0 (0%) | 16 (35%) |
| Time from symptom onset to blood sample, d | 8 (6-16) | 11 (7-16) | |
| 28-d mortality | 0 (0%) | 0 (0%) | 18 (39%) |
| Comorbidities | |||
| Obesity | 2 (8%) | 1 (5%) | 10 (22%) |
| Hypertension | 2 (8%) | 4 (18%) | 25 (54%)‡ |
| Diabetes | 0 (0%) | 1 (5%) | 16 (35%)‡ |
| Cancer | 0 (0%) | 0 (0%) | 4 (9%) |
| Heart disease§ | 0 (0%) | 0 (0%) | 3 (7%) |
| Presenting symptoms | |||
| Cough | 0 (0%) | 8 (36%) | 26 (57%) |
| Fever | 0 (0%) | 8 (36%) | 29 (63%) |
| Dyspnea | 0 (0%) | 3 (14%) | 29 (63%) |
| Headache | 0 (0%) | 7 (32%) | 5 (11%) |
| Anosmia | 0 (0%) | 6 (27%) | 11 (24%) |
| Laboratory findings at admission | |||
| Leukocytes, ×1000/µL | – | 7.6 (6.2-15.5) | 13 (9.1-18.4) |
| Lymphocytes, cells/µL | – | 2156 (2015-2933) | 1057 (567-1540) |
| Monocytes, cells/µL | – | 447 (308-620) | 672 (473-848) |
| Platelet count, ×1000/µL | – | 188 (26-198) | 194 (155-268) |
Numerical variables are represented as the median and the interquartile range, and qualitative variables are represented as the number and the percentage.
Dopamine, epinephrine/norepinephrine, vasopressin, or phenylephrine.
P < .05 compared with control. The qualitative variables were compared using the 2-tailed Fisher exact test, and the numerical variables using the t test for parametric and the Mann-Whitney U test for nonparametric distributions.
Coronary artery disease or congestive heart failure.